Search results
Results from the WOW.Com Content Network
Intuitive Surgical (NASDAQ: ISRG) is a healthcare company that makes robotic-assisted surgical devices. Intuitive Surgical's stock has been rallying, and it's up around 60% over the past 12 months.
Intuitive Surgical -- maker of the daVinci Robotic Surgical System -- and its investors have experienced quite the roller coaster over the past year. From medical professionals publicly ...
For the fiscal year 2017, Intuitive Surgical reported earnings of US$660 million, with an annual revenue of US$3.129 billion, an increase of 15.7% over the previous fiscal cycle. Intuitive Surgical's shares traded at over $307 per share, and its market capitalization was valued at over US$58 billion in November 2018. [10]
One of the most significant advancements in this period was the da Vinci Surgical System, which was approved by the FDA for use in surgical procedures in 2000 (Intuitive Surgical, 2021). The da Vinci system uses robotic arms to manipulate surgical instruments, allowing surgeons to perform complex procedures with greater accuracy and control. [ 9 ]
da Vinci patient-side component (left) and surgeon console (right) A surgeon console at the treatment centre of Addenbrooke's Hospital The da Vinci System consists of a surgeon's console that is typically in the same room as the patient, and a patient-side cart with three to four interactive robotic arms (depending on the model) controlled from the console.
Intuitive Surgical (NAS: ISRG) carries $192.3 million of goodwill and other intangibles on its balance sheet. Sometimes goodwill, especially when it's excessive, can foreshadow problems down the road.
For premium support please call: 800-290-4726 more ways to reach us
The agreement gave Intuitive Surgical an equity stake in Hansen and royalties on the future sales of Hansen Medical products. The full financial terms of the agreement were not made public. [3] Hansen Medical went public in 2006, raising $75 million in its initial public offering with two catheter systems under FDA review. The shares ...